LIVER Publication-derived

Organoid-Based Autologous Cell Therapy: Manufacturing and

Source Clevers et al. · Hubrecht Institute and Princess Maxima Center, Utrecht, Netherlands · 10.1038/s41556-019-0384-4

👤 Clevers H, Conder RK, Li VSW, Lutolf MP, Vallier L, Chan S, Grikscheit TC, Jensen KB, De Coppi P ⏱ 3360 min 🧫 Primary (Patient Biopsy to Clinical-Grade Organoid Product)

Abstract

Defines the end-to-end manufacturing pipeline for autologous intestinal organoid cell therapy from patient biopsy to transplantation-ready product within 4-6 weeks, including GMP production, quality control, cryopreservation, and delivery logistics.

Cell source

Primary (Patient Biopsy to Clinical-Grade Organoid Product)

Application

Manufacturing Pipeline

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Clevers et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence